| 1 |
35246210 | Perfect match: mTOR inhibitors and tuberous sclerosis complex. | 2022 Mar 4 |
1 |
| 2 |
33431351 | Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway. | 2021 Jan 8 |
1 |
| 3 |
33727259 | Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. | 2021 Jul 15 |
1 |
| 4 |
33911192 | Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. | 2021 Apr 28 |
1 |
| 5 |
33981751 | A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report. | 2021 Mar |
4 |
| 6 |
33986025 | Did Everolimus Break the Rules? | 2021 Jul 15 |
1 |
| 7 |
34349839 | Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. | 2021 |
2 |
| 8 |
34422335 | A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. | 2021 Jul |
3 |
| 9 |
34901059 | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex. | 2021 |
1 |
| 10 |
32222129 | Tuberous sclerosis: a review of the past, present, and future | 2020 Nov 3 |
1 |
| 11 |
32563542 | An Updated Review of Tuberous Sclerosis Complex-Associated Autism Spectrum Disorder. | 2020 Aug |
1 |
| 12 |
33575217 | Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma. | 2020 |
1 |
| 13 |
30327302 | PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. | 2019 Jan 15 |
2 |
| 14 |
31335226 | Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. | 2019 Oct |
6 |
| 15 |
31389395 | TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study. | 2019 Jul-Sep |
1 |
| 16 |
31791480 | Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children. | 2019 Dec |
2 |
| 17 |
29476223 | Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. | 2018 Apr |
1 |
| 18 |
29478616 | Tuberous sclerosis complex. | 2018 |
1 |
| 19 |
30159145 | Silent gonadotroph pituitary neuroendocrine tumor in a patient with tuberous sclerosis complex: evaluation of a possible molecular link. | 2018 |
2 |
| 20 |
27860334 | Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). | 2017 Jun |
1 |
| 21 |
28053551 | Genetics of tuberous sclerosis complex: implications for clinical practice. | 2017 |
1 |
| 22 |
28386314 | Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. | 2017 |
2 |
| 23 |
29296616 | Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. | 2017 Dec |
1 |
| 24 |
29344138 | Clinical and genetic analysis of tuberous sclerosis complex-associated renal angiomyolipoma in Chinese pedigrees. | 2017 Dec |
1 |
| 25 |
26927950 | The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. | 2016 Apr |
1 |
| 26 |
27680012 | Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications. | 2016 Sep 29 |
2 |
| 27 |
27809914 | Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study. | 2016 Nov 3 |
3 |
| 28 |
24929024 | Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. | 2015 Jan |
1 |
| 29 |
25344617 | Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus. | 2015 Feb |
1 |
| 30 |
26289591 | Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. | 2015 Dec |
3 |
| 31 |
26500758 | Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. | 2015 |
2 |
| 32 |
26706015 | Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex. | 2015 Dec |
1 |
| 33 |
24415439 | New treatments for bladder cancer: when will we make progress? | 2014 Mar |
1 |
| 34 |
25380949 | Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report. | 2014 Oct |
2 |
| 35 |
23446718 | [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway]. | 2013 Feb 22 |
1 |
| 36 |
23845174 | Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? | 2013 Nov |
3 |
| 37 |
24044547 | Is mTOR inhibition a systemic treatment for tuberous sclerosis? | 2013 Sep 17 |
2 |
| 38 |
24143074 | Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. | 2013 |
1 |
| 39 |
22923433 | Genome sequencing identifies a basis for everolimus sensitivity. | 2012 Oct 12 |
1 |
| 40 |
23730262 | mTOR Inhibitors in Tuberous Sclerosis Complex. | 2012 Dec |
2 |
| 41 |
21530413 | Pediatric epileptology. | 2011 Sep |
1 |
| 42 |
21806479 | Everolimus tablets for patients with subependymal giant cell astrocytoma. | 2011 Oct |
3 |
| 43 |
21916571 | Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. | 2011 Aug |
1 |